HIGHLIGHTS
- who: Mengmeng Lyu and collaborators from the Ethics statement The studies involving human participants were reviewed and approved by Ethics approval was obtained from the ethics committee of The Affiliated Cancer Hospital of Nanjing Medical University, approval number is , ke-kuai The patients/participants provided their written informed consent to participate in this study. have published the research: No obvious advantage of hyperthermic intraperitoneal chemotherapy after interval debulking surgery in the treatment of advanced ovarian cancer: A retrospective study, in the Journal: (JOURNAL)
- what: The results of the study showed a median PFS of 14 . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.